News
![DGAP-Adhoc: PAION AG: YICHANG HUMANWELL ERHÄLT MARKTZULASSUNG FÜR REMIMAZOLAM IN DER KURZSEDIERUNG IN CHINA](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-Adhoc: PAION AG: YICHANG HUMANWELL ERHÄLT MARKTZULASSUNG FÜR REMIMAZOLAM IN DER KURZSEDIERUNG IN CHINA
DGAP-Adhoc: PAION AG: YICHANG HUMANWELL ERHÄLT MARKTZULASSUNG FÜR REMIMAZOLAM IN DER KURZSEDIERUNG IN CHINA
DGAP-News: Biotest AG: Aufsichtsrat von Biotest verlängert Vorstandsbestellungen
DGAP-News: Biotest AG: Aufsichtsrat von Biotest verlängert Vorstandsbestellungen
DGAP-News: Biotest AG: Biotest Supervisory Board extends contracts with the Board of Management
DGAP-News: Biotest AG: Biotest Supervisory Board extends contracts with the Board of Management
DGAP-News: Biotest AG: Biotest reicht Phase II-Studie mit Trimodulin zur Behandlung von schwer erkrankten COVID-19 Patienten ein
DGAP-News: Biotest AG: Biotest reicht Phase II-Studie mit Trimodulin zur Behandlung von schwer erkrankten COVID-19 Patienten ein
DGAP-News: Biotest AG: Biotest submits phase II study with trimodulin for the treatment of severe COVID-19 patients
DGAP-News: Biotest AG: Biotest submits phase II study with trimodulin for the treatment of severe COVID-19 patients
![DGAP-News: US-LIZENZVEREINBARUNG FÜR BYFAVO (REMIMAZOLAM) ZWISCHEN PAION UND COSMO VON COSMO AN ACACIA ÜBERTRAGEN](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
DGAP-News: US-LIZENZVEREINBARUNG FÜR BYFAVO (REMIMAZOLAM) ZWISCHEN PAION UND COSMO VON COSMO AN ACACIA ÜBERTRAGEN
DGAP-News: US-LIZENZVEREINBARUNG FÜR BYFAVO (REMIMAZOLAM) ZWISCHEN PAION UND COSMO VON COSMO AN ACACIA ÜBERTRAGEN
![DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA
DGAP-News: U.S. LICENSE AGREEMENT FOR BYFAVOTM (REMIMAZOLAM) BETWEEN PAION AND COSMO ASSIGNED FROM COSMO TO ACACIA
![DGAP-News: NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
DGAP-News: NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock
DGAP-News: NanoViricides Closes On $11.5 Million Underwritten Public Offering of Common Stock
![DGAP-News: NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
DGAP-News: NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock
DGAP-News: NanoViricides, Inc. Prices $10.0 Million Underwritten Public Offering of Common Stock
![DGAP-News: PAION GIBT VOLLSTÄNDIGE WANDLUNG VON WANDELSCHULDVERSCHREIBUNGEN BEKANNT](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-News: PAION GIBT VOLLSTÄNDIGE WANDLUNG VON WANDELSCHULDVERSCHREIBUNGEN BEKANNT
DGAP-News: PAION GIBT VOLLSTÄNDIGE WANDLUNG VON WANDELSCHULDVERSCHREIBUNGEN BEKANNT
![DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES
DGAP-News: PAION REPORTS FULL CONVERSION OF CONVERTIBLE NOTES
![DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Veränderung im Vorstand der BRAIN AG - Chief Business Officer Ludger Roedder verlässt den Vorstand mit sofortiger Wirkung](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Veränderung im Vorstand der BRAIN AG - Chief Business Officer Ludger Roedder verlässt den Vorstand mit sofortiger Wirkung
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Veränderung im Vorstand der BRAIN AG - Chief Business Officer Ludger Roedder verlässt den Vorstand mit sofortiger Wirkung
![DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG - Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG - Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Change in the Management Board of BRAIN AG - Chief Business Officer Ludger Roedder is leaving the executive board with immediate effect
![DGAP-News: Molecular Partners AG: Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Molecular Partners AG: Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding
DGAP-News: Molecular Partners AG: Molecular Partners Successfully Completes the Launch of a Private Placement of 5,528,089 Shares by way of an Accelerated Bookbuilding
![DGAP-News: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-News: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-News: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVOTM) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
![DGAP-News: PAION GIBT MARKTZULASSUNG FÜR REMIMAZOLAM (BYFAVO) IN DER KURZSEDIERUNG IN DEN USA DURCH DIE FDA BEKANNT](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: PAION GIBT MARKTZULASSUNG FÜR REMIMAZOLAM (BYFAVO) IN DER KURZSEDIERUNG IN DEN USA DURCH DIE FDA BEKANNT
DGAP-News: PAION GIBT MARKTZULASSUNG FÜR REMIMAZOLAM (BYFAVO) IN DER KURZSEDIERUNG IN DEN USA DURCH DIE FDA BEKANNT
![DGAP-Adhoc: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
DGAP-Adhoc: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
DGAP-Adhoc: PAION ANNOUNCES U.S. FDA APPROVAL OF REMIMAZOLAM (BYFAVO) FOR THE INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION
![DGAP-News: B.R.A.I.N. AG purchases the outstanding 24.7% minority stake of WeissBioTech GmbH](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: B.R.A.I.N. AG purchases the outstanding 24.7% minority stake of WeissBioTech GmbH
DGAP-News: B.R.A.I.N. AG purchases the outstanding 24.7% minority stake of WeissBioTech GmbH
![DGAP-News: B.R.A.I.N. AG erwirbt ausstehende Minderheitsanteile (24,7%) der WeissBioTech GmbH](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-News: B.R.A.I.N. AG erwirbt ausstehende Minderheitsanteile (24,7%) der WeissBioTech GmbH
DGAP-News: B.R.A.I.N. AG erwirbt ausstehende Minderheitsanteile (24,7%) der WeissBioTech GmbH
![DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
DGAP-News: Abivax treats first patient in Phase 2b/3 ABX464 Covid-19 clinical trial
![DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
DGAP-News: Abivax behandelt ersten Patienten in der klinischen Phase 2b/3-Covid-19-Studie mit ABX464
![DGAP-News: NanoViricides Announces Addition to Russell Microcap(R) Index](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: NanoViricides Announces Addition to Russell Microcap(R) Index
DGAP-News: NanoViricides Announces Addition to Russell Microcap(R) Index
![DGAP-News: MagForce AG Publishes Financial Results for the Year 2019 and Operative Highlights](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
DGAP-News: MagForce AG Publishes Financial Results for the Year 2019 and Operative Highlights
DGAP-News: MagForce AG Publishes Financial Results for the Year 2019 and Operative Highlights
![DGAP-News: MagForce AG gibt Finanzergebnisse für das Geschäftsjahr 2019 und operative Highlights bekannt](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
DGAP-News: MagForce AG gibt Finanzergebnisse für das Geschäftsjahr 2019 und operative Highlights bekannt
DGAP-News: MagForce AG gibt Finanzergebnisse für das Geschäftsjahr 2019 und operative Highlights bekannt
![DGAP-Adhoc: HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.http://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWlE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--53b91026ff232fa7aa2f7da83a280c15c28ca459/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/haematoLogo.png?locale=us)
DGAP-Adhoc: HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.
DGAP-Adhoc: HAEMATO AG: HAEMATO AG: The Supervisory Board and the Executive Board have agreed that Mr Uwe Zimdars will leave the Executive Board of HAEMATO AG on June 30, 2020.